Community-acquired pneumonia

Lancet

Volumn 352, Issue 9136, 1998, Pages 1295-1302

  Brown, Patricia D ^a   Lerner, Stephen A ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DOXYCYCLINE; DOXYCYCLINE FOSFATEX; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; NAFCILLIN; PENICILLIN G; PENICILLIN V; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; VANCOMYCIN;

AGE; ANTIBIOTIC RESISTANCE; BRUSH BORDER; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY CARE; COMORBIDITY; CROSS RESISTANCE; DISEASE SEVERITY; DNA PROBE; DRUG HYPERSENSITIVITY; FIBEROPTIC BRONCHOSCOPY; FLUID THERAPY; GRAM STAINING; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; LEGIONELLA; META ANALYSIS; MICROBIOLOGY; MORTALITY; ORAL DRUG ADMINISTRATION; PENICILLIN RESISTANCE; PLEURA EFFUSION; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEROLOGY; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; VIRUS PNEUMONIA;

EID: 0032541830     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)02239-9     Document Type: Review

References (80)

1. 1 Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18: 501-05.
2. 2 Guest JF, Morris A. Community acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1998; 10: 1530-34.
3. 3 Centers for Disease Control and Prevention. Premature deaths, monthly mortality, and monthly physician contacts - United States. M M W R Morb Mortal Wkly Rep 1997; 46: 556.
4. 4 Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157: 1709-18.
5. 5 Lévy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988; 92: 43-48.
6. 6 Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; i: 671-74.
7. 7 Fang G, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307-16.
8. 8 Lim I, Shaw DR, Stanley DP, Lumb R, McLennan G. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust 1989; 151: 87-91.
9. 9 Porath A, Schlaeffer F, Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 1997; 34: 41-48.
10. 10 Bohte R, vanFurth R, van den Brock PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543-47.
11. 11 Lieberman D, Schlaeffer F, Bolden I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-84.
12. 12 Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508-15.
13. 13 Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312-18.
14. 14 Bartlett JG. Management of respiratory tract infections. Baltimore: Williams and Wilkins, 1997: 49.
15. 15 Moine P, Vercken J, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia: etiology, epidemiology, and prognostic factors. Chest 1994; 105: 1487-95.
16. 16 Woodhead M. Pneumonia in the elderly. J Antimicrob Chemother 1994; 34 (suppl A): 85-92.
17. 17 Lieberman D, Lieberman D, Porath A. Seasonal variation in community-acquired pneumonia. Eur Respir J 1996; 9: 2630-34.
18. 18 Metlay JP, Schulz R, Hi-Hwei L, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453-59.
19. 19 Chalasani NP, Valdecanas AL, Gopal AK, McGowen JE, Jurado RL. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. Chest 1995; 108: 932-36.
20. 20 Sahn SA. Management of complicated parapneumonia effusions. Am Rev Respir Dis 1993; 148: 813-17.
21. 21 American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26.
22. 22 British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50.
23. 23 Bartless JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-38.
24. 24 Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50: 339-44.
25. 25 Rein MF, Gwaltmer JM, O'Brien WM, et al. Accuracy of the gram's stain in identifying pneumococci in sputum. JAMA 1978; 239: 2671-73.
26. 26 Fine MJ, Orloff JJ, Rihs JD, et al. Evaluation of housestaff physicians' preparation and interpretation of sputum gram stains for community-acquired pneumonia. J Gen Intern Med 1991; 6: 189-98.
27. 27 Meehan TP, Fine MJ, Krunholz HM, et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-84.
28. 28 Ortquist A, Kelin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990; 97: 576-82.
29. 29 Edelstein PH. Legionnaires' disease. Clin Infect Dis 1993; 16: 741-49.
30. 30 Gaiydos CA, Eiden JJ, Oldach D, et al. Diagnosis of Chlaymdia pneumoniae infection in patients with community acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis 1994; 19: 157-60.
31. 31 Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275: 134-41.
32. 32 Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-23.
33. 33 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997; 336: 243-50.
34. 34 Austrian R. Confronting drug-resistant pneumococci. Ann Intern Med 1994; 121: 807-09.
35. 35 Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987: the pneumococcal surveillance working group. J Infect Dis 1991; 163: 1273-78.
36. 36 Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention Pneumococcal Sentinel Surveillance System. J Infect Dis 1996; 174: 986-93.
37. 37 Simor AE, Louie M, Canadian Bacterial Surveillance Network, Low DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2190-93.
38. 38 Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA 1996; 275: 194-98.
39. 39 Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-80.
40. 40 Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-96.
41. 41 Marton A. Pneumococcal antimicrobial resistance: the problem in Hungary. Clin Infect Dis 1992; 15: 106-11.
42. 42 Reinert RR, Lutticken R, Kaufhold A. Aktuelle Daten zur Antibiotikempfindlich-keiten von Streptococcus pneumoniae (Pneumokokken): die Bedeutung von penicillin resistenten Isolaten. Med Klin 1993; 88: 357-61.
43. 43 Moreillon P, Wenger A. Antibiotic resistance in pneumococci. Schweiz Med Wochenschr 1996; 126: 255-63.
44. 44 Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-86.
45. 45 Crewe-Brown HH, Karstaedt AS, Saunders GL, et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997; 25: 1165-72.
46. 46 Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052-59.
47. 47 Linares J, Alonso T, Pérez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother 1992; 30: 279-88.
48. 48 Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 478-80.
49. 49 Coffey TJ, Daniels M, McDougal LK, Dowson CG, Tenover FC, Spratt BG. Genetic analysis of clinical isolates of Streptococcus pneumoniaeith high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1995; 39: 1306-13.
50. 50 Krauss J, van der Linden M, Grebe T, Hakenbeck R. Penicillin-binding proteins 2x and 2b as primary PBP targets in Streptococcus pneumoniae. Microb Drug Resist 1996; 2: 183-86.
51. 51 Krauss J, Hakenbeck R. A mutation in the D,D-carboxypeptidase penicillin-binding protein 2 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604. Antimicrob Agents Chemother 1997; 41: 936-42.
52. 52 Goldstein FW, Acar JF. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 western Europe and USA collaborative surveillance study: The Alexander Project Collaborative Group. J Antimicrob Chemother 1996; 38 (suppl A): 71-84.
53. 53 Friedland IR , McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-82.
54. 54 Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594-97.
55. 55 Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm 1997; 54: 2569-83.
56. 56 Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53: 817-24.
57. 57 Tarlow MJ, Block SL, Harris J, Kolokathis A. Future indications for macrolides. Paediatr Infect Dis J 1997; 16: 457-62.
58. 58 Schrock J, Hackman BA, Plouffe JF. Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the E test. Diagn Microbiol Infect Dis 1997; 28: 221-23.
59. 59 File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72.
60. 60 Sparfloxacin and levofloxacin. Med Lett Drugs Ther 1997; 39: 41-43.
61. 61 Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110: 1499-506.
62. 62 Aubier M, Lode H, Gialdroni-Grassi G, et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 1996; 37 (suppl A): 73-82.
63. 63 Donowitz GR, Brandon ML, Salisbury JC, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative multicenter study. Clin Ther 1997; 19: 936-53.
64. 64 Topkis S, Swarz H, Breisch SA, Maroli AN. Efficacy and safety of grepafloxacin 600 mg daily for 10 daily in patients with community-acquired pneumonia. Clin Ther 1997; 19: 975-78.
65. 65 Grepafloxacin - a new fluoroquinolone. Med Lett Drugs Ther 1998; 40: 17-18.
66. 66 Gooding B-B, Jones RN. In vitro antimicrobial activity in CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993; 37: 349-53.
67. 67 Trovafloxacin. Med Lett Drugs Ther 1998; 40: 30-31.
68. 68 Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146: 920-23.
69. 69 Tan TQ, Mason EO Jr, Kaplan SL. Systemic infections due to Streptococcus pneumoniae relatively resistant to penicillin in a children's hospital: clinical management and outcome. Pediatrics 1992; 90: 928-33.
70. 70 Mandell LA, Bergeron MC, Gribble MJ, et al. Sequential antibiotic therapy: effective management and patient care. Can J Infect Dis 1995; 6: 306.
71. 71 Ramirez JS, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-76.
72. 72 Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-57.
73. 73 Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococal polysaccharide vaccine. N Engl J Med 1991; 325: 1454-60.
74. 74 Koivula I, Sten M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-90.
75. 75 Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77.
76. 76 Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. M M W R Morb Mortal Wkly Rep 1997; 46: 1-24.
77. 77 Ely EW. Pneumonia in the elderly: diagnostic and therapeutic challenges. Infect Med 1997; 14: 643-54.
78. 78 Centers for Disease Control and Prevention. Update on adult immunization: recommendations of the Advisory Committee on Immunization Practices. M M W R Morb Mortal Wkly Rep 1997; 40: 1-94.
79. 79 Centers for Disease Control and Prevention. Pneumococcal and influenza vaccination levels among adults aged > or =65 years -United States, 1995. M M W R Morb Mortal Wkly Rep 1997; 46: 913-19.
80. 80 Centers for Disease Control and Prevention. Missed opportunities for pneumo-coccal and influenza vaccination of Medicare pneumonia inpatients - 12 western states. M M W R Morb Mortal Wkly Rep 1997; 46: 919-23.